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SUMMARY – Primary premature ovarian insuffi  ciency (PPOI) is characterized by hypergonado-
tropic amenorrhea and hypoestrogenism in women under 40 years of age. PPOI incidence is 1:10,000 
in women aged 18-25, 1:1000 in women aged 25-30 and 1:100 in women aged 35-40. In 10%-28% of 
cases, PPOI causes primary and in 4%-18% secondary amenorrhea. Th e process is a consequence of 
accelerated oocyte atresia, diminished number of germinated cells, and central nervous system aging. 
Specifi c genes are responsible for the control of oocyte number undergoing the ovulation process and 
the time to cessation of the reproductive function. A positive family history of PPOI is found in 15% 
of women with PPOI, indicating the existing genetic etiology. Primary POI comprises genetic aber-
rations linked to chromosome X (monosomy, trisomy, translocation, deletion) or to autosomal chro-
mosome. Secondary POI implies surgical removal of ovaries, chemotherapy and radiotherapy, and 
infections. Diagnostic criteria include follicle stimulating hormone level >40 IU/L and estradiol level 
<50 pmol/L.
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Introduction
Premature ovarian insuffi  ciency (POI) is character-
ized by hypergonadotropic amenorrhea and hypoes-
trogenism in women under 40 years of age. Diagnostic 
criteria are follicle stimulating hormone (FSH) level 
>40 IU/L and estradiol (E2) level <50 pmol/L1. Th e 
POI incidence is 1:10,000 in women aged 18-25, 
1:1000 in women aged 25-30 and 1:100 in women 
aged 35-402. POI causes 10%-28% of primary amen-
orrhea and 4%-18% of secondary amenorrhea3. Th e 
onset of the disease is a consequence of an accelerated 
process of oocyte atresia, i.e. a diminished number of 
germinated cells, and maturation of the central ner-
vous system. Specifi c genes are responsible for the con-
trol of oocyte number undergoing ovulation process 
and cessation of the reproductive period4. A positive 
family history of POI was found in 15% of women 
with POI, confi rming the existing genetic etiology5,6.
Before the 20th week of gestation, the meiosis and 
mitosis processes go in parallel in the ovary and after 
that time, maturation and distribution of the future 
oocytes is completed. Th e number of oocytes is limited 
at birth; therefore, there will be no further production 
of this cell type. Th e maximum number of primordial 
follicles in the female fetus increases in 20-24 weeks of 
gestation, when the process of atresia starts. In the 
process of cessation, the number of primordial follicles 
decreases from 6-7 million to 1-2 million at birth, then 
to 300,000-400,000 on entering puberty. Th e ongoing 
process of steroidogenesis takes place up to the last fol-
licle exists. It is well known that typical climacteric 
symptoms start when the number of primordial folli-
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cles decreases below 2500 in both ovaries. Th e increase 
in FSH starts shortly after age 30, while the number of 
the rest of the follicles correlates with further FSH in-
crease after age 40.
Diff erence between the primordial and primary 
follicles is determined by layers of granulosa cells sur-
rounding oocytes, with one layer in primordial follicles 
and multiple layers of cuboid granulosa cells in pri-
mary follicles. One of the possible etiologic factors for 
primary POI might be a disorder at the level of trans-
mission from primordial to primary follicles.
Every woman younger than 40 with amenorrheic 
period is obliged to seek help at the gynecologist of-
fi ce. Symptoms of POI are psychological (nervousness, 
hot fl ushes, excitability, insomnia, depression, loss of 
libido, lack of concentration) and physical (parts of 
body feeling numb or tingling, muscle or joint pains, 
body weight increase). Hormone analysis (FSH, lu-
teinizing hormone (LH), estradiol (E2), antimüllerian 
hormone (AMH), inhibin B, prolactin, progesterone, 
testosterone, free thyroxine (fT4) and thyroid-stimu-
lating hormone (TSH)) is necessary. POI diagnosis is 
confi rmed by FSH >40 IU/L and estradiol <50 pmol/L 
in women aged <40. When Addison’s disease is sus-
pected, adrenocorticotopic hormone (ACTH) stimu-
lation test is performed. Karyotyping is necessary in 
women younger than 30. Ovarian biopsy is not a rou-
tine procedure. Dual energy x-ray absorptiometry is 
recommended in screening for osteoporosis.
Etiology
Premature ovarian insuffi  ciency is divided into two 
main groups: primary POI (PPOI) and secondary POI 
(SPOI). Th e etiology of PPOI is shown in Table 1.
Genetic Causes
Follicle-stimulating hormone receptor gene mutation
In some families, familial PPOI occurrence is fi g-
ured out (grandmother, mother and daughter) earlier 
in every consecutive generation. One of the possible 
causes is a mutation in the FSH receptor gene. Inacti-
vated mutation of the FSH receptor (FSHR) gene 
damages adenylyl cyclase stimulation, while the recep-
tor remains captured inside the cell. FSH is essential 
for normal follicle maturation. In the last 50 days of its 
development, maturation of the follicle is blocked. A 
large number of small follicles with no ability to prog-
ress further are present in women with PPOI. Th e 
most frequent mutation is present in exon 7 of the 
FSHR gene (FSHR, located on 2p chromosome), re-
placing Ala to Val at protein level. Mutations of the 
FSHR gene are related to FSH resistance, which leads 
to an increased FSH level and a decreased estrogen 
serum level. Women with total FSH resistance have 
hypoplastic ovaries and primary amenorrhea7. Some 
other forms of FSHR have been identifi ed in women 
with PPOI and secondary amenorrhea, moderate ova-
ry dysfunction and family history of PPOI8. Th ese 
variances are rare and there is no direct infl uence in the 
etiology of PPOI9,10.
Structural alterations of chromosome
X chromosome alterations are the most frequent 
genetic causes of PPOI, accounting for 12% of cas-
es6,11-13. Th ese alterations comprise complete monoso-
my or partial deletion, duplication or translocation of 
the X chromosome, as follows:
a) Turner syndrome (45X0) – the prevalence of X 
monosomy is 1:2500. Turner syndrome is char-
acterized by lower height than normal, gonadal 
dysgenesis and primary amenorrhea14. Oocyte 
deprivation begins mainly in the early childhood 
as a consequence of accelerated follicle atresia14.
b) Trisomy X (47 XXX) – usually does not cause 
particular problems, but in some cases PPOI 
Table 1. Etiology of primary premature ovarian 
insuffi  ciency
Genetic causes •  FSH receptor mutation, 
transcription factor mutation
•  Fragile X chromosome
•  Structural alteration and 
monosomy of the X chromosome
•  Chromosome X trisomy with or 
without mosaicism
•  Myotonic dystrophy
Enzyme 
defi ciency





•  Biologically inactive gonadotropin
•  a and b subgroup defi ciency
•  Receptor/post-receptor defi ciency
Idiopathic •  Unknown cause
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appears15. Th e genes located on the X chromo-
some are critical for the normal function of the 
ovary, thus any abnormality can induce PPOI9,16. 
Groswani et al.17 found that 3.8% of women 
with PPOI had X chromosome trisomy.
c) Fragile X chromosome – expansion of trinucle-
otide tandem repeat CGG at the 5’UTR region 
of the FMR 1 gene (Xq27.3) was found in some 
PPOI cases. Th e CGG tandem repeat variation 
length is defi ned as normal (≤50), premutation 
(50-200) and full mutation (≥200 tandem re-
peats). Full mutation is associated with a fragile 
X syndrome, where mental retardation is the 
crucial sign18. Recently, some epidemiological 
studies have found connection of the premuta-
tion FMR1 gene with PPOI in 6% of sporadic 
cases and 13% of family PPOI19. FMR1 protein 
is expressed in fetal germ cells, as well as in 
granulosa cells of the mature follicle20.
Th e carriers of the premutation alleles can exhibit 3 
clinical forms, i.e. PPOI; lack of concentration/atten-
tion and other psychological changes; and neurologic 
disorders (tremor, ataxia, Parkinson’s disease).
Hegerman et al.21 indicated the association of PPOI 
with tremor, ataxia and Parkinson’s disease, which could 
be one more proof of the important role of sex steroids 
in the brain.
In the most prominent number of cases, PPOI 
seems to be a multifactorial disorder. From this point 
of view, studies of the gene-DNA polymorphism are 
crucial in clarifying PPOI etiology. DNA or gene 
polymorphisms express the variants in hereditary ba-
sis, which could be found in the general population. 
From the phenotype point of view, they are in princi-
ple ‘benign’, but could also represent predisposition for 
certain, usually multifactorial disorders22.
Polymorphisms in the genes encoding steroid hor-
mone receptors, as well as their connection with diff er-
ent reproductive system disorders have been intensive-
ly studied in the last few years. It is well known that 
the forehand expression and proper coordination of 
the genes are fundamental for the normal growth and 
development of the ovary23. Polymorphisms important 
for PPOI are mostly unknown despite of the patho-
genic defects identifi ed in some candidate genes24,25. 
Th erefore, in most PPOI cases, no clear etiologic fac-
tors were found, so they were classifi ed as idiopathic 
PPOI.
Oocyte-specifi c transcription factors
In homozygous FOXL2 mutation, granulosa cells 
do not undergo transition from squamous to cuboid, 
and it is exactly the layer where the mistake comes 
from. Th is is the reason for the absence of secondary 
follicles, so oocyte atresia occurs26. Th e genes specifi -
cally expressed in oocyte are regulated through the 
specifi c transcription factors12. Mutations are identi-
fi ed in several genes encoding transcriptional factors 
important for folliculogenesis, i.e. NRA1, NOBOX, 
FIGLA and FOXL227-29.
Nuclear Receptor subfamily fi fth group term 1 
(NR5A1), known as steroidogenic factor 1, is a nuclear 
receptor which is implicated in early gonadal diff eren-
tiation29,30. Th e NR5A1 gene is located at 9q33.3. Ste-
roidogenesis is modulated through the regulation of 
the genes involved in the hypothalamic-pituitary-
-steroidogenetic axis, such as: STAR, CYP11A1, 
 CYP17A1, CYP19A1, LH and INHA30.
Homeobox protein (NOBOX) – the newborn ova-
ry homeobox gene is an oocyte – is a specifi c expressed 
gene with an essential role in folliculogenesis and so 
one of the candidate genes for PPOI28. It is responsible 
for the specifi c transcriptional factor which regulates 
the genes important for early folliculogenesis31. Using 
the knockout mouse model, it has been proven that 
NOBOX regulates diff erent gene expressions specifi c 
for the oocyte, including BMP-15 and GDF-931. Th e 
lack of NOBOX expression is connected with acceler-
ated oocyte loss after mouse parturition30.
Folliculogenesis Specifi c Basic Helix-Loop-Helix 
(FIGLA), the embryo-specifi c transcription factor, 
regulates expression of the genes responsible for the 
initiation of folliculogenesis and coding the zona pel-
lucida proteins (ZP1, ZP2 and ZP3) essential for fe-
cundation and embryo survival. It is crucial for oocyte 
rebellion and formatting the primordial follicles32. Its 
lack leads to accelerated loss of postnatal primordial 
follicles in mice33.
Forkhead Box L2 (FOXL2) gene is located on 
3q23. Foxl2 protein exudes in the granulosa cells from 
the embryogenesis until the adult age27. Th e mutation 
of this gene leads to failure of granulosa cell diff eren-
tiation, which induces early activation and exhaustion 
of primordial follicles33. Th e FOXL2 mutation is iden-
tifi ed in 5% of non-syndromic PPOI patients, suggest-
ing the possibility of idiopathic PPOI occurrence27.
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Helix-loop-helix (SOHLH) 1 and 2 are transcrip-
tion factors important for PPOI. Th ey are responsible 
for the follicle early growth and diff erentiation by con-
trol of a number of genes including NOBOX, FIGLA, 
BMP-15 and GDF-912. Th e SOHLH2 gene is loca-
ted on chromosome 13. Th is gene codes one of the fac-
tors which are crucial for spermatogenesis, oogenesis 
and folliculogenesis12. Zhao et al.34 found three new 
SOHLH1 variations as the potential cause of PPOI in 
364 Chinese women with PPOI.
Folliculogenesis growth factors
Bone morphogenetic protein 15 (BMI-15) is a 
member of the transforming growth factor ß (TGF-ß) 
superfamily. Th e gene is located at Xq11.2 and encodes 
an oocyte-specifi c growth and diff erentiation factor35. 
BMP-15 is involved in stimulating folliculogenesis 
and promoting follicle maturation by regulating gran-
ulosa cell diff erentiation and proliferation36.
Th e growth diff erentiation factor 9 (GDF9) gene, a 
homologue of BMP-15, is also member of the TGF-ß 
superfamily and is located at 5q23.2. Like BMP-15, 
GDF-9 is oocyte specifi c and regulates primordial fol-
licle development and stimulates granulosa cell prolif-
eration and follicle maturation30. GDF-9 is also 
thought to play a role in steroidogenesis and modula-
tion of FSH sensitivity in granulosa cell37.
Inhibin alpha (INHA) gene encodes the alpha sub-
unit of inhibin A and inhibin B, which together with 
their corresponding beta units (INHBA and INHBB), 
a class of dimeric glycoproteins, also belong to the 
TGF-ß superfamily38. Inhibins are produced primarily 
by granulosa cells and act on the pituitary by inhibiting 
FSH production39. Decreased inhibin production is 
associated with increased FSH production, leading to 
enhanced follicle recruitment and increased depletion 
of the follicular pool11. Indeed, women with idiopathic 
POI have lower serum levels of inhibins and higher 
serum FSH as compared with age-matched fertile 
controls, suggesting that inhibins play an important 
role in normal ovarian function39.
Some of the gene candidates and their function in 
the pathogenesis of PPOI are shown in Table 240.
Receptors
Estrogen receptors
Estrogen receptors (ER) are transcriptional factors 
that occur in granulosa cells, as well as in many other 
tissues and are involved in the expression of diff erent 
genes included in the cell growth and development41. 
Th ere are two estrogen receptors known as ERa and 
ERb. Estrogen regulates gonadotropin release via ERa 
action, labeled with ESR1 on the hypothalamic-hy-
pophyseal axis42. Th e ERa gene is located on 6q25-27 
chromosome. Its promoter area comprises a polymor-
phic chain TA tandem repeat, associated with heredi-
tary premature ovarian dysfunction, as well as with 
diminished bone mineral density and endometriosis.
Th e ERb gene is located on the 14q23-24 chromo-
some. Estrogen improves folliculogenesis via ERb42. 
On uncoding 3’-region of this gene, a polymorphic 
CA tandem repeat chain was recently identifi ed, spec-
ulating about its connection with bone mineral density 
in women43. Th e functional role of these two polymor-
phisms has not yet been fully clarifi ed; however, there 
is some evidence for their infl uence on the structure 
and function of the genes44. Th e connection between 
Table 2. Some of the gene candidates and their function in 
the pathogenesis of primary premature ovarian 
insuffi  ciency
Gene Gene locus Function of a gene product
FMR1 Xq27.3 Oocyte development 
and maturation
NR5A 9q33.3 Steroidogenesis of the ovary
NOBOX 7q25 Early folliculogenesis
FIGLA 2q12 Zona pellucida gene 
regulation
FOXL2 3q23 Granulosa cell 
diff erentiation and follicle 
development
SOHL1/2 13q13.3 Early folliculogenesis
BMP-15 Zq11.2 Follicular maturation
GDF-9 5q23.2 Follicular maturation
INHA 2q33-36 Folliculogenesis regulation 
via FSH inhibition
FSHR 2p21 Growth and development 
of the follicle, 
steroidogenesis
LHR 2p21 Follicle maturation, 
steroidogenesis, ovulation
ESR1 6q25.1 Growth and development 
of the follicle
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these two microsatellite polymorphisms and PPOI has 
been demonstrated45,46.
Progesterone receptor
Th e progesterone receptor (PGR) gene is situated 
on the 11q22 chromosome. A number of polymorphic 
regions have been discovered in this gene, and one of 
the functionally most important is the insertion/dele-
tion of ALu sequence of 306 bp. It is believed that the 
insertion allele, labeled as PROGINS, has a protective 
function in the female reproductive system, either in 
the homozygous or heterozygous state47.
Androgen receptor
Androgen receptor (AR) belongs to the nuclear 
transcriptional factors family. Th e only AR gene is lo-
cated on chromosome X, Xq11-12. In this gene, poly-
morphism of a diff erent number of CAG tandem re-
peats encoding the polyglutaminic chain of diff erent 
lengths, has been identifi ed. Th is chain infl uences the 
receptor function, so that longer tandem repeats are 
connected with a lower functional level of the recep-
tor48. In fact, in the fi rst exon of the AR gene, there are 
2 microsatellite polymorphisms; the fi rst one with 
CAG tandem repeats – (CAG)n and the second one 
with GGN tandem repeats – (GGN)n. A limited 
number of studies have found correlation of CAG rep-
etitions in AR gene and PPOI49,50, while others did 
not confi rm this correlation46,51. For the GGN tandem 
repeat in Indian women, a signifi cant correlation with 
PPOI has been reported51.
Enzyme Defi ciency
One of the etiologic factors for PPOI is defi ciency 
of 17-a hydroxylase (17OH), as well as galactose-
1-phosphate uridyltransferase (GALT). According 
the study by Waggoner et al., shortly after puberty, 
81% of aff ected women develop ovarian insuffi  ciency 
together with primary or secondary amenorrhea52.
Typical characteristics of women with the lack of 
17OH are primary amenorrhea, high levels of FSH, 
LH, progesterone, deoxycorticosterone, hypertension 
and hyperpotassium alkalosis. Intracellular accumula-
tion of galactose metabolite or lacking glycosylation 
decreases germ cell reserve53.
Conclusion
Today, PPOI is considered as a multifactorial dis-
ease, where the phenotype is most probably the result 
of sequence variation in more than one gene. Ethni-
cally distinct populations show diff erences in the gene-
regulating pathways and genes causing PPOI.
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Sažetak
GENETSKA ETIOLOGIJA PRIJEVREMENE INSUFICIJENCIJE JAJNIKA
M. Franić-Ivanišević, D. Franić, M. Ivović, M. Tančić-Gajić, Lj. Marina, M. Barac i S. Vujović
Primarna prijevremena insufi cijencija jajnika (PPIJ) je sindrom koji je obilježen hipergonadotropnom amenorejom i 
 hipoestrogenizmom. Incidencija PPIJ je 1:10.000 kod žena starosti 18-25 godina, 1:1000 kod žena starosti 25-30 godina i 
1:100 kod žena starosti 35-40 godina. U 10%-28% slučajeva PPIJ je uzrok primarnih, a u 4%-18% sekundarnih amenoreja. 
Bolest nastaje kao posljedica ubrzanog procesa atrezije oocita, smanjenja broja germinativnih stanica i starenja središnjeg 
živčanog sustava. Specifi čni geni su odgovorni za kontrolu broja oocita koji prolaze proces ovulacije i vrijeme prekida repro-
duktivne funkcije. Pozitivna obiteljska anamneza PPIJ nađena je u oko 15% žena s PPIJ, što ukazuje na postojanje određene 
genetske etiologije. Primarna insufi cijencija jajnika (PIJ) dijeli se na primarnu i sekundarnu. U primarnu PIJ spadaju genetske 
aberacije vezane za kromosom X (monosomije, trisomije, translokacije, delecije) ili one vezane za autosomne kromosome. U 
sekundarnu PIJ spadaju kirurško odstranjenje jajnika, liječenje kemoterapijom i radioterapijom te infekcije. Simptomi su 
razdražljivost, nemir, gubitak libida, depresija, nesanica, dekoncentracija, napadaji vrućine, povišenje tjelesne težine, suhoća 
vagine i drugih sluznica. Kriteriji za dijagnozu su folikulostimulirajući hormon viši od 40 IJ/L i estradiol (E2) niži od 50 
pmol/L kod žena mlađih od 40 godina.
Ključne riječi: Primarna insufi cijencija ovarija – etiologija; Primarna insufi cijencija ovarija – genetika
